Olutasidenib DDI Study for IDH1-Mutated Cancers
This study is testing how olutasidenib, a drug for cancers with an IDH1 mutation, interacts with other medications in your body. It's looking at how your body processes olutasidenib and a 'cocktail' of other drugs (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates). You can join if you are an adult with an IDH1 mutation-positive cancer, such as acute myeloid leukemia (AML), glioma, cholangiocarcinoma, or other solid tumors, and meet other health criteria. The main goal is to measure the levels of these probe drugs in your blood to understand any interactions. The study plans to enroll 16 participants, but its current recruitment status is unclear.
- Study design
- This is an open-label study, meaning you and your doctors will know what treatments you are receiving. It is designed to understand drug interactions and plans to include 16 participants.
- What's involved
- You will receive olutasidenib daily for several weeks, with an option to continue treatment for a longer period. You will also receive single doses of other probe drugs on specific days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your blood levels of the probe drugs will be measured for up to 96 hours after each administration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07486713
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Recruiting
PHASE4Ages 18+InterventionalRigel Pharmaceuticals
~16 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:OlutasidenibCYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs
Measured over Up to 96 hours after each probe drug administration.
+1 more outcome measured
Conditions
Where it's being run
2 sites across 2 statesCalifornia1
New York1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Adult male or female ≥ 18 years of age at the time of signing the informed consent form
Must have an Eastern Cooperative Oncology Group performance status ≤ 2.
Must have recovered from the non-hematologic toxic effects of prior treatment to Grade ≤ 1, or baseline value (excluding infertility, alopecia, or Grade 1 neuropathy)
Must have a diagnosis of IDH1m+ malignancy to be treated with olutasidenib (e.g. acute myeloid leukemia \[AML\], gastrointestinal \[GI\] cancers, glioma). Patient should not have received olutasidenib within the 2 weeks prior to the first dose of study drug.
Patient must have an adequate organ function, defined by the following:
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values ≤ 2.5 × upper limit of normal (ULN).
Bilirubin ≤ 1.5× ULN (≤ 3 × ULN in patients with Gilbert Syndrome) or ≤ 3 × ULN for patients with AML involvement.
Creatinine clearance ≥ 30 mL/min using Cockcroft-Gault equation.
Female patients who are women of childbearing potential (WOCBP) must have a negative serum (β-hCG) pregnancy test at screening and negative urine test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug. WOCBP are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.
WOCBP, must agree to use two methods of birth control (e.g. hormonal and a barrier method such as a condom), or must be considered highly unlikely to conceive during the dosing period and for 3 months after last study treatment.
Male patients with female partners of childbearing potential may be enrolled if they both agree to use highly effective methods of contraception during the dosing period and for 3 months after last study treatment.
Male patients must refrain from donating sperm during the dosing period and for 3 months after last study treatment.
Exclusion
Female patients who are pregnant or breastfeeding.
Patients who are active smokers. Those who have ceased smoking \> 1 month before the Screening Visit will be allowed.
Ingestion of alcohol within 72 hours prior to first study drug administration and during the study period.
Any patient's who plans to become pregnant or father a child (including ova or sperm donation) while enrolled in this study or within 3 months after last dose of study drug.
Known allergy or history of hypersensitivity to study drugs or their excipients.
Human immunodeficiency virus (HIV) positivity.
Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or by RNA polymerase chain reaction (PCR) at screening.
Any patient's with a serious infection requiring intravenous or systemic antibiotics within 7 days prior to initiation of study treatment, or any active infection that, in the opinion of the Investigator, could impact patient's safety (e.g. COVID-19).
Use of concomitant medications that are moderate or strong CYP1A2, 2B6, 2C8, 2C9, 2C19, and/or 3A4 inhibitors within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study drug
Use of concomitant medications that are moderate or strong CYP1A2, 2B6, 2C8, 2C9, 2C19, and/or 3A4 inducers within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
History of or active, clinically significant, cardiovascular, respiratory, GI, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorder that, in the Investigator's opinion (or following review by the Sponsor), could affect the conduct of the study or the absorption, metabolism or excretion of the study treatment.
If less than the minimum time has elapsed from prior anticancer treatment to first dose of study treatment as follows:
History of prior second malignancy unless disease-free for ≥ 12 months or considered surgically cured. Patients with nonmelanoma skin cancers or with carcinomas in situ at any time following curative intent surgery and low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected are also eligible.
Patients with symptomatic central nervous system metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy.
Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \> 480 milliseconds \[msec\]) (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 1) using Fridericia's QT correction formula.
Patients with New York Heart Association Class III or IV heart failure.
What this trial measures
- Area Under the Plasma Concentration-Time Curve (AUC) of Probe DrugsUp to 96 hours after each probe drug administration.
To evaluate how olutasidenib affects the overall exposure of several test drugs (probe substrates) that are used to measure the activity of certain enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4) and a drug transporter (OATP1B1). This will be assessed by measuring the area under the plasma concentration-time curve after the probe drugs are taken alone and again after treatment with olutasidenib.
- Maximum Plasma Concentration (Cmax) of Probe DrugsUp to 96 hours after each probe drug administration.
To evaluate how olutasidenib affects the peak levels of probe drugs in the blood after they are taken alone and again after treatment with olutasidenib.